Lunai Bioworks (NASDAQ:LNAI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lunai Bioworks (NASDAQ:LNAI) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lunai Bioworks in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Lunai Bioworks has an average rating of “Sell”.

Lunai Bioworks Stock Performance

Lunai Bioworks stock opened at $0.94 on Friday. The stock has a market cap of $22.10 million, a PE ratio of -13.48 and a beta of 0.40. The firm has a 50-day moving average of $1.08. Lunai Bioworks has a 1 year low of $0.81 and a 1 year high of $14.00.

Lunai Bioworks (NASDAQ:LNAI) last posted its quarterly earnings results on Friday, November 14th. The company reported $0.13 earnings per share for the quarter.

Institutional Investors Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks at the end of the most recent reporting period. 71.41% of the stock is currently owned by institutional investors.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.